Fresh analysis indicates that individuals who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass far faster than those who stop traditional diet and exercise regimens.
Published data in a leading medical journal points out that while obese individuals often shed a large proportion of their body weight while using the jabs, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.
"People using such treatments should be cognizant of the risk of fast weight regain when the therapy ends," warns expert Dr. Susan Jebb.
That rate of recovery means a reversion to original mass within about 18 months.
Weighing Treatments
The study, which reviewed dozens of studies involving thousands of participants, contrasted the effects of GLP-1 agonists with older methods.
Researchers note that individuals who shed pounds through diet and exercise usually have a slower creep back—around 100 grams monthly—once they finish.
Understanding the Fast Regain
Nutrition scientists suggest the mode of action of the injections accounts for the heightened regain.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels several times higher than the body's typical production might result in the body to generate a reduced amount of its endogenous GLP-1, and may also lessen sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this medication results in appetite is unsuppressed, making binge eating a significant risk."
An Ongoing Condition?
Medical guidelines recommend the jabs for people with weight-linked health risks, alongside prescribed lifestyle changes.
A number of clinicians say that, given the likelihood of relapse, the therapy should be considered long-term.
This opinion is echoed by pharmaceutical companies, who note that the results "emphasize the long-term nature of excess weight," comparing it to managing diseases like hypertension.
Patient Testimonies
Individuals who have stopped the medication report a intense resurgence of hunger.
"It was like something flipping and I was suddenly starving," said a patient.
This challenge is worsened if users have not developed permanent dietary or behavioural modifications during therapy.
Growing Adoption
Survey data indicate that millions of adults in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Use is greater among women than men.
- The 40s and 50s demographic shows the highest level of interest.
- Many access the medications through private prescriptions rather than public health services.
Finally, clinicians stress that while GLP-1 drugs are potent agents for weight loss, they are not a magic fix and long-term success hinges on combined behavioural management.
